Document Detail


Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
MedLine Citation:
PMID:  22344964     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: The aim of the study was to investigate variations in anti-infliximab (IFX) antibody (Ab) levels and clinical implications thereof in patients with inflammatory bowel disease (IBD). METHODS: A retrospective, explorative, single-center study of patients with IBD who developed anti-IFX Ab and in whom anti-IFX Ab were reassessed. RESULTS: IFX was administered to 316 patients; anti-IFX Ab was determined in 180 patients and detected in 83 (46%). During ongoing IFX maintenance therapy, anti-IFX Ab disappeared at later reassessment in two-thirds of patients with clinical response after median 4 (3-5) infusions. In contrast, anti-IFX Ab persisted in all patients without clinical response. Anti-IFX Ab appeared pharmacologically active, as IFX levels were high when anti-IFX Ab disappeared (median 3.7 μg/mL, interquartile range [IQR] 2.8-5.5), while undetectable or low when anti-IFX Ab persisted (median 0 μg/mL, IQR 0-0). In 56 patients, anti-IFX Ab were assessed after IFX discontinuation. The proportion of patients with anti-IFX Ab gradually declined over time, with a few patients having anti-IFX Ab up to about 4 years after initial assessment. No variables were associated with anti-IFX Ab disappearance in multivariate analysis. CONCLUSIONS: Discontinuation of IFX is advisable in patients with inadequate response and repeat positive anti-IFX Ab measurements. Anti-IFX Ab can persist for years after discontinuation, which could impact efficacy and safety at retreatment. Continued IFX treatment may, however, be considered in patients with clinical response and a single positive anti-IFX Ab measurement, as anti-IFX Ab disappears in two-thirds of these during continued treatment. (Inflamm Bowel Dis 2012;).
Authors:
Casper Steenholdt; Magid Al-Khalaf; Jørn Brynskov; Klaus Bendtzen; Ole Ø Thomsen; Mark A Ainsworth
Related Documents :
22463834 - Why does my patient have lymphadenopathy or splenomegaly?
15942204 - Utility of electrogastrography in differentiating parkinson's disease with or without g...
10201434 - Affective symptoms in multiple system atrophy and parkinson's disease: response to levo...
20198714 - Discriminative power of different nonmotor signs in early parkinson's disease. a case-c...
9541444 - Ophthalmic findings of newly diagnosed leprosy patients in istanbul leprosy hospital, t...
1115834 - "early-peak" carbon monoxide production in certain erythropoietic disorders.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-16
Journal Detail:
Title:  Inflammatory bowel diseases     Volume:  -     ISSN:  1536-4844     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508162     Medline TA:  Inflamm Bowel Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Affiliation:
Department of Medical Gastroenterology, Herlev Hospital, Denmark. steenholdt@brygge.dk.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Age-related proteomic changes in the subventricular zone and their association with neural stem/prog...
Next Document:  MHC-dependent mate choice in humans: why genomic patterns from the HapMap European American dataset ...